The Explore Study

Currently Recruiting

Up to $200

Brisbane, Australia

Epstein–Barr virus (EBV) is a very common virus that infects more than 9 out of 10 adults worldwide. It is best known for causing infectious mononucleosis, sometimes called “glandular fever or mono ”, particularly when infection occurs during the teenage years or early adulthood.

EBV has also been linked to certain cancers, autoimmune conditions, and multiple sclerosis.

Once a person is infected, EBV remains in the body for life. The virus usually stays inactive (dormant), but it can reactivate from time to time, often without causing symptoms.

The study vaccine uses mRNA technology, which has been widely used and studied in COVID‑19 vaccines. mRNA vaccines provide instructions to the body that help the immune system recognise and fight a virus. The mRNA does not contain live virus and does not remain in the body.

Apply now Speak with us 1300 617 687

Join our clinical trial

This is a first-in-human (FIH) study, meaning it is the first time the investigational vaccine is being tested in people. Investigational means that the vaccine is still being studied and has not yet been approved for general use by Australian health authorities. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. It is not known whether the study vaccine may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur.

Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions.

Why participate?

  • Participation in a monitored clinical environment
  • Scheduled study visits
  • Support from a professional medical team
  • Reimbursement for your time and commitment

Trial details

Study duration

  • 1 Pre-Screening Visit

Ethics

An independent ethics committee has approved this clinical trial. 

Are you a match?

Age

18 - 25 years old

Remuneration

Up to $200 *with screening reimbursement. Please see T&Cs.

Gender

Male or Female

BMI

BMI 18 - 40 kg/m2

Commitment

Appointment only, 1 clinic visit

Medical condition

Not taking any medications

Register Your Interest for The Passage Study

Thank you for your interest in participating in a clinical trial. This study is evaluating an investigational drug that may help address conditions involving inflammation and tissue scarring.

 The study is scheduled for March 2026, and you’ll need to be available during that time.

This form takes 2–3 minutes to complete, and your information will remain confidential, used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1300 590 848 or schedule a call.


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg





















Step 2 of 3
Medical History

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow participants who are (social) smokers.

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Referral Information



Consent to Information Use and Future Contact